NHS trust investigates after ‘unnecessary delay' for thousands of patients
The patients were waiting for ENT appointments provided by Medway NHS Foundation Trust (MNFT) operating out of Medway Maritime Hospital in Gillingham and Darent Valley Hospital in Dartford.
The trust said it was 'very sorry' for the delays caused to patients and has commissioned an independent investigation.
Some 4,279 adults and children were awaiting a first outpatient appointment after a referral, while 4,570 existing patients were awaiting a follow-up appointment, diagnostic test or procedure.
Approximately 20% of those affected are children, and a few patients have waited as much as five years to be seen, the trust confirmed.
Jonathan Wade, chief executive of Dartford and Gravesham NHS Trust and interim chief executive of Medway NHS Foundation Trust, said: 'We are very sorry for the unnecessary delay experienced by some of our ENT patients.
'We are in the process of contacting patients to apologise and make arrangements for them to be seen as quickly as possible.'
The delays affected patients predominantly in the Dartford, Gravesham, Swanley, Bexley and Greenwich areas.
When these referrals were first received, they were reviewed by a clinician and assessed as routine, meaning that no urgent concerns, such as cancer, were identified at the time, the trust has said.
Mr Wade continued: 'We have taken immediate action to ensure referrals to this service are correctly managed, with stronger oversight and improved systems in place.
'A full, independent investigation has been commissioned to understand how the error occurred and if anyone has come to harm as a result of these unnecessary delays.
'We are committed to learning from this so that it does not happen again.'
MNFT declined to comment on whether the commissioned investigation has begun, and how long it will take.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Biophotonics: Strategic Market and Tech Overview
"A strategic overview of biophotonics innovations, market trends, and cross-industry applications shaping the future of healthcare and life sciences." BOSTON, July 23, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Biophotonics: Technologies and Global Markets" was valued at $62.6 billion in 2024 and it is expected to grow from $68.4 billion in 2025 to reach $113.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2030. The report offers a comprehensive look at the biophotonics market, examining its growth across applications like imaging, sensing, and light-based therapies. It analyzes usage trends in medical diagnostics, therapeutics, and testing, as well as regional dynamics across North America, Europe, Asia-Pacific, and other global markets. Market drivers, challenges, and innovations in material design are discussed, along with insights into leading companies and their offerings. This report is particularly relevant today as the biophotonics market is undergoing rapid transformation driven by technological advances and increased demand for healthcare. Innovations in optical technologies are expanding the scope of biophotonics across multiple industries, particularly in non-invasive diagnostics and therapeutic applications. The rising prevalence of chronic diseases further fuels the need for advanced, precise, and less intrusive medical solutions. In this dynamic environment, staying informed about market trends and emerging opportunities is crucial for stakeholders aiming to leverage the full potential of biophotonics. The factors driving the market's growth include: Growing Prevalence of Chronic Diseases: The increasing global burden of chronic illnesses like cancer, diabetes, and cardiovascular diseases is driving demand for advanced diagnostic and therapeutic tools. Biophotonics offers precise, real-time imaging and monitoring solutions that support early detection and effective treatment, making it essential in modern healthcare. Rising Demand for Non-Invasive Diagnostics: Patients and clinicians prefer non-invasive diagnostic methods for their safety, comfort, and efficiency. Biophotonics technologies such as optical coherence tomography and Raman spectroscopy enable accurate, painless diagnostics, reducing the need for surgical procedures and improving patient outcomes. Advances in Optical Technologies: Rapid innovation in lasers, fiber optics, and imaging systems has enhanced the performance and accessibility of biophotonics tools. These advances allow for higher resolution, faster data processing, and integration with AI, expanding their use in both clinical and research settings. Expansion into Non-Medical Applications: Biophotonics is finding applications in industries like agriculture, food safety, environmental monitoring, and forensics. Its ability to detect biological and chemical changes makes it valuable for quality control, pollution detection, and security, broadening its market reach. Increasing Penetration of Personalized Medicine and Precision Healthcare: As healthcare moves toward personalized and precision approaches, biophotonics plays a key role by enabling molecular-level diagnostics and targeted therapies. Its capabilities support tailored treatment plans based on individual patient profiles, aligning with the future of medicine. Request a sample copy of the global market for biophotonics report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $62.6 billion Market size forecast $113.1 billion Growth rate CAGR of 10.6% from 2025 to 2030 Segments covered Application, Technique, End Use and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (Latin America and the Middle East and Africa) Countries covered U.S., Canada, Germany, U.K., France, Japan, China and India Market drivers Growing prevalence of chronic diseases. Rising demand for non-invasive diagnostics. Advances in optical technologies. Expansion into non-medical applications. Increasing penetration of personalized medicine and precision healthcare. Interesting facts: In vitro biophotonics accounted for 72% of the biophotonics market in 2024 because of the rising need for early disease detection, better optical imaging technologies, and increased use of personalized medicine. North America accounted for 52.8% of the biophotonics market in 2024 thanks to its strong technical infrastructure, sizable investments in research, and demand from healthcare, life sciences, and biotech industries. Growth was also boosted by partnerships and innovations from leading companies Thermo Fisher Scientific, Danaher Corp., and Hamamatsu Photonics. Combining biophotonics with nanotechnology has led to major improvements in ultra-sensitive diagnostic tools and targeted treatments. This has made disease diagnosis more accurate and helped create personalized treatment plans that improve patient outcomes. Emerging startups Lithium Lasers DYSIS Medical Inc. Sascan Meditech Pvt Ltd The report addresses the following questions: What is the projected size and growth rate of the market?- The market is projected to reach $113.1 billion by the end of 2030, growing at a CAGR of 10.6% during the forecast period. Which factors are driving the growth of the market?- The key factors driving the market include the growing prevalence of chronic diseases, rising demand for non-invasive diagnostics, and advances in optical technologies. Which market segments are covered in the report?- The four market segments covered are application, technique, end use and region. Which end-use segment will be dominant through 2030?- The medical diagnostics end-use segment is expected to dominate the market through 2030, driven by the increasing demand for non-invasive and real-time diagnostic techniques, advancements in optical imaging technologies, and the rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Which region has the largest market share?- North America holds the largest share of the global market, due to its advanced technical infrastructure, sizable R&D investments, and demand from sectors such as healthcare, life sciences, and biotech. Market leaders include: BECTON DICKINSON BIOPHOTONICS DIAGNOSTICS GMBH EXCELITAS TECHNOLOGIES CORP. GLENBROOK TECHNOLOGIES HAMAMATSU PHOTONICS K.K. IDEX IPG PHOTONICS CORP. ISMO BIOPHOTONICS PVT. LTD. LUMA BIOPHOTONICS OLYMPUS CORP. OXFORD INSTRUMENTS OZ OPTICS LTD. THERMO FISHER SCIENTIFIC INC. TOPTICA PHOTONICS AG ZEISS Related reports: Photonic Integrated Circuits: Global Markets with Special Focus on Silicon Photonics: The report offers a comprehensive overview of the photonic integrated circuits (PICs) market, examining key components such as transceivers, lasers, modulators, detectors, MUX/DEMUX, and optical amplifiers. It highlights their application across sectors like optical communication, sensing, biophotonics, and signal processing. The study provides regional insights spanning North America, Europe, Asia-Pacific, and the Rest of the World, while analyzing market dynamics, including drivers, challenges, and emerging trends. It also emphasizes advances in material design and performance and concludes with analysis of the competitive landscape. Medical Imaging: A BCC Research Outlook: The report offers a detailed analysis of the medical imaging market, covering key product types such as X-ray, ultrasound, MRI, CT, nuclear imaging, and emerging modalities like optical and photoacoustic imaging. It provides sales forecasts segmented by product, application, and end user, while examining regional dynamics, market drivers, and the competitive landscape. The study also highlights technological innovations shaping the future of medical imaging. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC
Gizmodo
an hour ago
- Gizmodo
FDA's New Drug Approval AI Is Generating Fake Studies: Report
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI will soon be used to approve new drugs 'very, very quickly.' But a new report from CNN confirms all our worst fears. Elsa, the FDA's AI tool, is spitting out fake studies. CNN spoke with six current and former employees at the FDA, three of whom have used Elsa for work that they described as helpful, like creating meeting notes and summaries. But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI as 'hallucinating.' The AI will also misrepresent research, according to these employees. 'Anything that you don't have time to double-check is unreliable. It hallucinates confidently,' one unnamed FDA employee told CNN. And that's the big problem with all AI chatbots. They need to be double-checked for accuracy, often creating even more work for the human behind the computer if they care about the quality of their output at all. People who insist that AI actually saves them time are often fooling themselves, with one recent study of programmers showing that tasks took 20% longer with AI, even among people who were convinced they were more efficient. Kennedy's Make America Healthy Again (MAHA) commission issued a report back in May that was later found to be filled with citations for fake studies. An analysis from the nonprofit news outlet NOTUS found that at least seven studies cited didn't even exist, with many more misrepresenting what was actually said in a given study. We still don't know if the commission used Elsa to generate that report. FDA Commissioner Marty Makary initially deployed Elsa across the agency on June 2, and an internal slide leaked to Gizmodo bragged that the system was 'cost-effective,' only costing $12,000 in its first week. Makary said that Elsa was 'ahead of schedule and under budget' when he first announced the AI rollout. But it seems like you get what you pay for. If you don't care about the accuracy of your work, Elsa sounds like a great tool for allowing you to get slop out the door faster, generating garbage studies that could potentially have real consequences for public health in the U.S. CNN notes that if an FDA employee asks Elsa to generate a one-paragraph summary of a 20-page paper on a new drug, there's no simple way to know if that summary is accurate. And even if the summary is more or less accurate, what if there's something within that 20-page report that would be a big red flag for any human with expertise? The only way to know for sure if something was missed or if the summary is accurate is to actually read the report. The FDA employees who spoke with CNN said they tested Elsa by asking basic questions like how many drugs of a certain class have been approved for children. Elsa confidently gave wrong answers, and while it apparently apologized when it was corrected, a robot being 'sorry' doesn't really fix anything. We still don't know the workflow being deployed when Kennedy says AI will allow the FDA to approve new drugs, but he testified in June to a House subcommittee that it's already being used to 'increase the speed of drug approvals.' The secretary, whose extremist anti-vaccine beliefs didn't keep him from becoming a public health leader, seems intent on injecting unproven technologies into mainstream science. Kennedy also testified to Congress that he wants every American to be strapped with a wearable health device within the next four years. As it happens, President Trump's pick for Surgeon General, Casey Means, owns a wearables company called Levels that monitors glucose levels in people who aren't diabetic. There's absolutely no reason that people without diabetes need to constantly monitor their glucose levels, according to experts. Means, a close ally of Kennedy, has not yet been confirmed by the Senate. The FDA didn't respond to questions emailed on Wednesday about what the agency is doing to address Elsa's fake study problem. Makary acknowledged to CNN that Elsa could 'potentially hallucinate,' but that's 'no different' from other large language models and generative AI. And he's not wrong on that. The problem is that AI is not fit for purpose when it's consistently just making things up. But that won't stop folks from continuing to believe that AI is somehow magic.
Yahoo
an hour ago
- Yahoo
Boston Scientific lifts annual profit forecast, sees smaller tariff impact
By Padmanabhan Ananthan (Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the previously projected amount. Shares of the company rose 4.8% in morning trading following the results. "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100 million, down from a $200 million estimate," CFO John Monson said during a call with analysts. The company expects to offset the remaining tariff impact through strong sales performance, favorable product mix and spending control, Monson added. A rise in surgical procedures has boosted sales for medical device makers such as Boston Scientific, helping counter broader concerns about healthcare spending. Executives credited strong trial results and expanded product indications for fueling physician adoption of key cardiovascular devices such as Watchman and Farapulse, the firm's main growth drivers that saw steady quarterly demand. The company said the proposed rules by the Centers for Medicare & Medicaid Services regarding certain cardiac procedures would further benefit its technologies. Farapulse, which is approved in the U.S. for some patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the pulsed field ablation (PFA) market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. JP Morgan analyst Robbie Marcus said the profit forecast raise was larger than many had expected, especially given Boston Scientific is now moving past the initial U.S. rollout of Farapulse. "That said, the outlook still appears conservative to us," Marcus added. Boston Scientific now expects 2025 adjusted profit of $2.95 to $2.99 per share, up from its prior view of $2.87 to $2.94. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to LSEG. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
